|
|
||||||||
agonist in vivo
1 Unité Propre de Recherche et d'Enseignement Supérieur-Equipe d'Accueil 3447 Lésions-Réparation: Remodelage Cardiaque et Artériel, Faculté de Médecine, Université Henri Poincaré, Nancy I; 2 Département d'Hématologie Biologique, and 3 Département d'Anesthésie-Réanimation Chirurgicale, Centre Hospitalier Universitaire Brabois, 54500 Vandoeuvre-les-Nancy; 4 Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch; and 5 Département d'Anesthésie-Réanimation Chirurgicale, Centre Hospitalier Universitaire Hôpital Central, 54000 Nancy, France
We have previously shown that
all-trans retinoic acid (atRA), the active metabolite of
vitamin A, enhances the activation of the inducible nitric oxide
synthase (NOS II) pathway, a component of innate immunity, in rats in
vivo. We investigated the relative contribution of retinoic acid
receptor-
(RAR
) and retinoid X receptors (RXRs) to NOS II
activation triggered by LPS. Five-day supplementation with 10 mg/kg of
either atRA or the RAR
selective agonist Ro-40-6055, but not with 10 mg/kg of the pan-RXR agonist Ro-25-7386, enhanced the LPS-induced NOS
II mRNA, protein expression in liver, and plasma nitrite/nitrate
concentration. Both atRA and the RAR
agonist (but not the RXR
agonist) increased the number of peripheral T helper lymphocytes and
plasma interferon-
concentration. Synergism between retinoids and
LPS on NOS II activation within an organ coincided with synergism on
interferon regulatory factor-1 mRNA expression but not with the level
of expression of the RAR
protein. These results suggest that, in
vivo, atRA activates NOS II through RAR
and contributes to
characterizing the complex effect of retinoids on the host
inflammatory/immune response.
synthetic retinoids; inducible nitric oxide synthase; T helper lymphocyte; interferon type II; interferon regulatory factor-1
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |